In conclusion, the present results showed no significant difference in PFS and OS between the chemotherapy and TKI groups for second‐line treatment in EGFR‐mutated NSCLC patients with T790M‐negative mutation that received EGFR tyrosine kinase inhibitors as first‐line treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.